<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635854</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/15/7738</org_study_id>
    <secondary_id>15 7738 02</secondary_id>
    <nct_id>NCT02635854</nct_id>
  </id_info>
  <brief_title>Study of Platelet Activation in Septic Shock Patients</brief_title>
  <acronym>PASS</acronym>
  <official_title>Study of Platelet Activation in Septic Shock Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some studies have shown that antiplatelets agents could reduce organ dysfunction in septic
      shock in mice and human models. Platelets are actors in immunity and their activation can be
      complicated by tissue damage with vascular occlusions which can lead to organ dysfunction.
      Investigators can hypothesize an increase in platelet activation and in leukocyte-platelet
      aggregates in septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of platelets activation markers expression (CD62-P, antibody CD63, CD42b)</measure>
    <time_frame>T0 at the admission in intensive care unit</time_frame>
    <description>Specific platelet activation markers and circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit for patients in test group and during the orthopedic surgical anesthesia consultation for patients in control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of platelets activation markers expression (CD62-P, CD63, CD42b)</measure>
    <time_frame>T48 hours after admission in intensive care unit</time_frame>
    <description>Specific platelet activation markers and circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood 48 hours later admission in intensive care unit only for patients in test group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of leukocyte-platelet aggregates</measure>
    <time_frame>T0 at the admission in intensive care unit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of leukocyte-platelet aggregates formation</measure>
    <time_frame>T0 at the admission in intensive care unit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of leukocyte-platelet aggregates rate and septic shock severity.</measure>
    <time_frame>T0 at the admission in intensive care unit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of platelet activation in subjects treated or not with antiplatelet agents.</measure>
    <time_frame>T0 at the admission in intensive care unit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group (Septic choc group) includes 15 patients suffering from septic shock in intensive care unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group (Orthopedic surgery group) includes 15 patients recruited from the orthopedic surgical anesthesia consultation programmed for a prosthetic hip or knee pose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Septic choc group</intervention_name>
    <description>Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Orthopedic surgery group</intervention_name>
    <description>Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        EXPERIMENTAL GROUP

          -  Patient who possibly gave an oral agreement to inclusion and may sign a consent once
             out of intensive care

          -  Patients hospitalized in general intensive care

          -  Patient hospitalized for less than 72 hours

          -  Patient suffering from severe sepsis, whatever their origin, with hypotension (PAs
             &lt;90mmHg) despite adequate fluid resuscitation and vasoactive requiring the use of
             amines, with hypoperfusion and / or at least one organ dysfunction ( septic shock)

          -  Patient with a Sequential Organ Failure Assessment (SOFA) score&gt; 8 (or&gt; 2 in an organ)
             in the first 24 hours

          -  Patient enjoying a social security scheme or equivalent

        CONTROL GROUP

          -  Signed informed consent

          -  Patient seen anesthesia consultation for orthopedic knee prosthesis of laying or hip
             with a negative balance infectious

          -  Patient enjoying a social security scheme or equivalent

        Exclusion Criteria:

        EXPERIMENTAL GROUP

          -  Patient on safeguarding justice, guardianship

          -  Patient suffering from a haematological malignancy (leukemia, lymphoma ...)

          -  Patient suffering from thrombocytopenia or constitutional thrombopathy

          -  Pregnant

        CONTROL GROUP

          -  Patient on safeguarding justice, guardianship

          -  Patient with infectious positive balance (dental, urinary tract) prior to surgery

          -  Patient suffering from a haematological malignancy (leukemia, lymphoma ...)

          -  Patient suffering from thrombocytopenia or constitutional thrombopathy

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny BOUNES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Valerio-Rojas JC, Jaffer IJ, Kor DJ, Gajic O, Cartin-Ceba R. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract. 2013;2013:782573. doi: 10.1155/2013/782573. Epub 2013 Feb 20.</citation>
    <PMID>23509620</PMID>
  </reference>
  <reference>
    <citation>Rahman M, Gustafsson D, Wang Y, Thorlacius H, Braun OÖ. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets. 2014;25(4):257-63. doi: 10.3109/09537104.2013.809520. Epub 2013 Jul 15.</citation>
    <PMID>23855479</PMID>
  </reference>
  <reference>
    <citation>Li Z, Yang F, Dunn S, Gross AK, Smyth SS. Platelets as immune mediators: their role in host defense responses and sepsis. Thromb Res. 2011 Mar;127(3):184-8. doi: 10.1016/j.thromres.2010.10.010. Epub 2010 Nov 13. Review.</citation>
    <PMID>21075430</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukocyte and platelet aggregates</keyword>
  <keyword>platelet activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

